Guidance for evaluation of novel applications for COVID-19
Since the inception of the COVID-19 pandemic, ICMR has received over 190 requests for evaluation of molecules/AYUSH regimens/products/technologies/diagnostic kits, etc. In view of ICMR’s involvement in diagnosis, research, surveillance, clinical trials and validation of diagnostic kits for COVID-19, the Cabinet Secretary has directed ICMR to partner with various Science Departments like Department of Science and Technology (DST), Department of Biotechnology (DBT) and Council of Scientific and Industrial Research (CSIR) for evaluating the antiviral properties of investigational products/repurposed drugs/devices/technologies, etc.
